$ALMS

$6.51 -$0.27 (3.98%) Close

$ALMS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$ALMS Management Team

Mr. Mark Bradley

Chief Development Officer

Age 60

Compensation -

Sex Male

Dr. Joern Drappa

Chief Medical Officer

Head - Research and Development

Age 60

Compensation -

Sex Male

Mr. Roy Hardiman

Chief Business and Strategy Officer

Age 65

Compensation $3.217M USD

Sex Male

Ms. Sara Klein

Chief Legal Officer and Corporate Secretary

Age 61

Compensation -

Sex Female

Mr. Martin Babler

Chairman of the Board

President

Chief Executive Officer

Age 60

Compensation $10.66M USD

Sex Male

Mr. John Schroer

Chief Financial Officer

Age 59

Compensation -

Sex Male

Mr. Derrick Richardson

Senior Vice President - People and Culture

Age 55

Compensation -

Sex Male

Dr. David Goldstein

Chief Scientific Officer

Age 59

Compensation $3.244M USD

Sex Male

Name / Title	Age	Compensation	Sex
Mr. Mark Bradley Chief Development Officer	60	-	Male
Dr. Joern Drappa Chief Medical Officer Head - Research and Development	60	-	Male
Mr. Roy Hardiman Chief Business and Strategy Officer	65	$3.217M USD	Male
Ms. Sara Klein Chief Legal Officer and Corporate Secretary	61	-	Female
Mr. Martin Babler Chairman of the Board President Chief Executive Officer	60	$10.66M USD	Male
Mr. John Schroer Chief Financial Officer	59	-	Male
Mr. Derrick Richardson Senior Vice President - People and Culture	55	-	Male
Dr. David Goldstein Chief Scientific Officer	59	$3.244M USD	Male

Board of Directors

From the proxy statement filed May 18, 2026

Directors

serving now

Independent

0 of 1

stated in the proxy; 7 not stated

Average tenure

3.6 years

from year joined

CEO also chairs the board

Yes

Martin Babler

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Martin Babler CEO, Board chair	61	2021 5 years	Not independent	None stated	Prelude Therapeutics Inc.	Paid as CEO
Alan B. Colowick, M.D., M.P.H.	64	2021 5 years	Not stated	None stated	None stated	Not stated
Patrick Machado, J.D.	62	2024 2 years	Not stated	None stated	Arcus Biosciences, Inc., Xenon Pharmaceuticals, Inc.	$226,307
Srinivas Akkaraju, M.D., Ph.D.	58	2024 2 years	Not stated	Science and Technology	vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., Inventiva S.A.	$213,958
Sapna Srivastava, Ph.D. Lead independent director	55	2022 4 years	Not stated	Nominating and Corporate Governance · Chair	Aura Biosciences, Inc., Nuvalent, Inc.	$225,730
James B. Tananbaum, M.D.	63	2021 5 years	Not stated	Compensation	None stated	Not stated
Lynn Tetrault, J.D.	64	2025 1 year	Not stated	None stated	NeoGenomics, Inc.	$190,139
Zhengbin (Bing) Yao, Ph.D.	60	2021 5 years	Not stated	Science and Technology · Chair	Visen Pharmaceuticals	$212,667

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed May 18, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Comments

Company Executives

$ALMS Management Team

Mr. Mark Bradley

Dr. Joern Drappa

Mr. Roy Hardiman

Ms. Sara Klein

Mr. Martin Babler

Mr. John Schroer

Mr. Derrick Richardson

Dr. David Goldstein

Board of Directors

Related-party transactions

No related-party transactions disclosed